Bis(2-Chloroethyl)amine hydrochloride
Bis(2-Chloroethyl)amine hydrochloride structure
|
Common Name | Bis(2-Chloroethyl)amine hydrochloride | ||
|---|---|---|---|---|
| CAS Number | 821-48-7 | Molecular Weight | 178.49 | |
| Density | 1.125 g/cm3 | Boiling Point | 204.2ºC at 760 mmHg | |
| Molecular Formula | C4H10Cl3N | Melting Point | 212-214 °C(lit.) | |
| MSDS | Chinese USA | Flash Point | 77.3ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Occupational exposure to nor-nitrogen mustard: chemical and biological monitoring.
Toxicol. Ind. Health 11(1) , 89-97, (1995) Nor-nitrogen mustard is an alkylating agent used in kilogram quantities in the production of various cytostatics. It has been shown to be mutagenic in vitro, and therefore must be regarded as a health hazard. We have studied the environment and blood of a sma... |
|
|
Basic principles in preclinical cancer chemotherapy.
J. Cancer Res. Clin. Oncol. 116(5) , 411-24, (1990)
|
|
|
Covalent binding of nitrogen mustards to the cysteine-34 residue in human serum albumin.
Arch. Toxicol. 76(2) , 83-8, (2002) Covalent binding of various clinically important nitrogen mustards to the cysteine-34 residue of human serum albumin, in vitro and in vivo, is demonstrated. A rapid method for detection of these adducts is presented, based on liquid chromatography-tandem mass... |
|
|
The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
Biol. Mass Spectrom. 23(3) , 149-58, (1994) A method is described for the determination of the antitumour drug cyclophosphamide and six stable metabolites in plasma of cancer patients, namely dechloroethyl-cyclophosphamide, 4-keto-cyclophosphamide, carboxy-phosphamide, alcophosphamide, nor-nitrogen mus... |
|
|
Oxazolidonylethyl adducts to hemoglobin and DNA following nornitrogen mustard exposure.
Chem. Biol. Interact. 99(1-3) , 263-75, (1996) Formation of adducts to hemoglobin (Hb) and DNA of nornitrogen mustard (NNM) was studied with the aim of developing a method for monitoring exposure to NNM. Adducts to N-terminal valines in Hb were studied by the N-alkyl Edman method using pentafluorophenyl i... |
|
|
The effect of estramustine, nor-nitrogen mustard and tauromustine on macromolecular labelling in the human prostatic tumour cell line 1013L.
Pharmacol. Toxicol. 64(1) , 9-13, (1989) To further clarify the mode of action of estramustine, the influence on macromolecular synthesis in the human prostatic tumour cell line 1013L was investigated. Cell treatment with estramustine, nor-nitrogen mustard and tauromustine, followed by radioactive n... |
|
|
Estramustine-induced mitotic arrest in two human prostatic carcinoma cell lines DU 145 and PC-3.
Prostate 5(1) , 93-100, (1984) In growth proliferation experiments on two human prostatic carcinoma cell lines, DU 145 cells were found to be more sensitive to the cytotoxic effect of estramustine and nor-nitrogen mustard than PC-3 cells. Estramustine was, however, much more cytotoxic in b... |
|
|
Growth and cell survival following treatment with estramustine nor-nitrogen mustard, estradiol and testosterone of a human prostatic cancer cell line (DU 145).
J. Urol. 127(4) , 818-22, (1982) Estramustine at concentrations ranging from 3-40 x 10(-6) M inhibited the cell growth and clonogenic survival of a human prostatic carcinoma cell line (DU 145). This cell line was found to be unresponsive to estradiol and testosterone at concentrations rangin... |
|
|
Cytogenetic toxicity of cyclophosphamide and its metabolites in vitro.
Cytogenet. Cell Genet. 26(2-4) , 108-16, (1980) The effects of cyclophosphamide and three of its known metabolites (nitrogen mustard, acrolein, and nor-nitrogen mustard on chromosome breakage and sister chromatid exchange (SCE) were analyzed in vitro with and without the presence of a metabolic activating ... |
|
|
The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy.
Br. J. Clin. Pharmacol. 10(4) , 327-35, (1980)
|